A Soft Tissue Sarcoma Market Research Report By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy

Soft Tissue Sarcoma Market Size was evaluated at USD 3,248.52 Million in 2023 and is expected to increase to USD 6,204.02 Million by 2032, with a compound yearly growth rate (CAGR) of 7.67% over the forecast period (2024-2032). New product introductions, growing usage of newer medicines, and a wider target demographic are all significant market drivers boosting growth.

The launch of new goods, widespread use of innovative treatments, and an expansion of the target population are all key market drivers promoting market growth. The discovery and development of innovative treatments is a key driver of the soft tissue sarcoma market. Over the last decade, there has been an increase in the availability of novel medications and therapies for treating soft tissue sarcoma. Patients and clinicians alike benefit from the expanded therapy options and increased effectiveness enabled by these groundbreaking medications.

Market Segment insights
The global soft tissue sarcoma market is divided into four types: angiosarcoma, epithelioid sarcoma, gastrointestinal stromal tumor (GIST), and others. The Angiosarcoma segment dominated the market in 2023, while the Gastrointestinal Stromal Tumor (GIST) sector grew the fastest during the projected period.

The Global Soft Tissue Sarcoma Market is split into Diagnosis and Treatment. The Diagnostic sector dominated the market in 2023, while the Treatment segment is the fastest expanding category during the projected period. Diagnosis is further divided into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others such as PET scan and X-ray. Treatment is further classified as targeted therapy, chemotherapy, anti-angiogenic drugs, radiation therapy, and surgery.

The Global Soft Tissue Sarcoma Market is divided into three end user segments: hospitals and clinics, cancer research centers, and others. The Hospitals and Clinics segment accounted for the biggest market share in 2023 and is expected to grow the quickest over the forecast period.

Regional insights
The analysis covers market insights for North America, Europe, Asia-Pacific, and the rest of the world. North America led the soft tissue sarcoma market in 2022, followed by Europe and the Asia-Pacific region. This is due to the high prevalence of soft tissue sarcoma in North America and Europe, as well as the availability of sophisticated healthcare infrastructure and R&D activities in these areas.

The European Soft Tissue Sarcoma market is the second largest contributor to the global market. In December 2021, the European Medicines Agency (EMA) granted conditional marketing clearance for Tazverik (tazemetostat) in the treatment of epithelioid sarcoma in adults.

Furthermore, the Asia Pacific Soft Tissue Sarcoma market is predicted to expand at the highest compound annual growth rate (CAGR) throughout the forecast period. In September 2021, the China National Medical Products Administration (NMPA) approved Ayvakit (avapritinib) as a treatment for unresectable or metastatic gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma.

Major Players
Major players in the Soft Tissue Sarcoma market are GlaxoSmithKline plc (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services Inc. (US), and others.